

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Larotrectinib for treating advanced solid tumours with TRK fusions ID1299

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Bayer (Larotrectinib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Sick Children • Butterfly Thyroid Cancer Trust • Black Health Agency • Breast Cancer Care • Breast Cancer Now • Breast Cancer UK • British Lung Foundation • British Skin Foundation • Cancer 52 • Cancer Black Care • Cancer Equality • Cancer Laryngectomee Trust • Changing Faces • Childhood Cancer Parents Alliance • Children's Cancer and Leukaemia Group • Children with Cancer • CLIC Sargent • Get-A-Head • Haven • HAWC • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Kidney Cancer Support Network • Kidney Cancer UK • Kidney Care UK • Kidney Research UK • Let's Face It • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Mouth Cancer Foundation 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • All Wales Therapeutics and Toxicology Centre • Association of Renal Industries • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Health and Safety Executive • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee • Welsh Kidney Patients Association <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Dermatological Surgery • Cochrane Childhood Cancer Group • Cochrane Skin Group • Head and Neck Cancer Research Trust • Institute of Cancer Research • MRC Clinical Trials Unit • Myfanwy Townsend Melanoma

Provisional matrix for the technology appraisal of larotrectinib for treating advanced solid tumours with TRK fusions ID1299 Issue date: July 2018

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Muslim Council of Britain • National Association Of Laryngectomee Clubs • National Children’s Bureau • National Kidney Federation • Roy Castle Lung Cancer Foundation • Sarcoma UK • Solving Kid’s Cancer • South Asian Health Foundation • Specialised Healthcare Alliance • Swallows Head and Neck Cancer Support Group • Teenage Cancer Trust • Tenovus Cancer Care • The Royal Marsden Cancer Charity • Together for Short Lives <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Association of Dermatologists • British Association of Endocrine and Thyroid Surgeons • British Association of Skin Cancer Specialist Nurses • British Dermatological Nursing Group • Association of Respiratory Nurse Specialists • British Geriatrics Society • British Institute of Radiology • British Renal Society • British Psychosocial Oncology Society • British Sarcoma Group • British Thoracic Oncology Group • British Thoracic Society • British Thyroid Association • British Uro-oncology Group • Cancer Research UK • Children's Cancer & Leukaemia Group • Melanoma Focus • National Lung Cancer Forum for Nurses • Primary Care Dermatology Society • Renal Association • Royal College of General Practitioners 	<p>Research Fund</p> <ul style="list-style-type: none"> • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Skin Cancer Research Fund • Skin Treatment & Research Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

Provisional matrix for the technology appraisal of larotrectinib for treating advanced solid tumours with TRK fusions ID1299 Issue date: July 2018

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Health Forum • UK Clinical Pharmacy Association • UK Oncology Nursing Society • UK Renal Pharmacy Group <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS North East Hampshire and Farnham CCG • NHS Swale CCG • Welsh Government 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.